

## **WorkBeads enable scale-up of Nemysis Ltd's nutritional deficiency candidates**

**On December 21 2023, Bio-Works confirmed a new order of WorkBeads, the company's product line for advanced protein purification, to Nemysis Ltd, an Irish developer of bioactive substances designed to target nutritional disorders and deficiencies. The order, worth approximately 2.5 MSEK, will enable Nemysis to scale-up one of its programs to minimize gastrointestinal disorders.**

"Bio-Works is very pleased to be able to support Nemysis in its mission to create products which prevent the negative side effects of nutrient disorders and deficiency," said Jonathan Royce, CEO of Bio-Works Technologies. "This order is evidence that our strategy to create unique purification products is in line with the needs of a diversifying platform of biotherapeutic molecules."

"We have been pleased with the product performance and technical support we have received from Bio-Works during the first production runs for this project, and we are happy to see our partnership continue as we scale-up clinical production during 2024," said Cristina Comelli, R&D Director at Nemysis Ltd.

Nemysis Ltd is an Irish company focused on development and production of bioactive substances identified as having large market potential, coupled with unmet patient needs, and where it can identify and harness innovative solutions. Nemysis' therapeutic focus is on nutritional disorders and deficiencies, with particular attention to minimise adverse gastrointestinal side effects, common to existing available solutions.

### **Contacts**

For more information, please visit the Bio-Works homepage at, [www.bio-works.com](http://www.bio-works.com) or contact: Jonathan Royce, CEO, e-mail: [jonathan.royce@bio-works.com](mailto:jonathan.royce@bio-works.com), phone: +46 70 1434143.

### **About Bio-Works**

Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works' next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.

Bio-Works' headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North ("BIOWKS"), and FNCA Sweden AB, +46 (0) 8-528 00 399, [info@fnca.se](mailto:info@fnca.se), is appointed Certified Adviser. For more information, [www.bio-works.com](http://www.bio-works.com).

**Attachments**[WorkBeads enable scale-up of Nemysis Ltd's nutritional deficiency candidates](#)